{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:04:07Z","timestamp":1774969447990,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The development of diagnostic tools capable of accurately identifying the pathophysiology of mild cognitive impairment (MCI) has become a crucial target considering the claim that disease-modifying treatments should be administered as early as possible in the disease course. Transcranial magnetic stimulation (TMS) protocols have demonstrated analytical validity in discriminating different forms of dementia; however, its value in daily clinical practice in MCI subjects is still unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the clinical value of TMS compared to amyloid markers on diagnostic confidence and accuracy in MCI subjects, considering clinicians\u2019 expertise.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred seven MCI subjects were included and classified as MCI-Alzheimer disease (MCI-AD), MCI-frontotemporal dementia (MCI-FTD), MCI-dementia with Lewy bodies (MCI-DLB), or MCI-other in a three-step process based on (i) demographic, clinical, and neuropsychological evaluation (clinical work-up); (ii) clinical work-up PLUS amyloidosis markers or clinical work-up PLUS TMS measures; and (iii) clinical work-up PLUS both markers. Two blinded neurologists with different clinical expertise were asked to express a diagnostic confidence for each MCI subgroup, and ROC curve analyses were performed at each step.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The addition of TMS markers to clinical work-up significantly increased the diagnostic confidence for MCI-AD (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), MCI-FTD (<jats:italic>p<\/jats:italic>\u2009=\u20090.044), and MCI-DLB (<jats:italic>p<\/jats:italic>\u2009=\u20090.033) compared to clinical work-up alone, but not for MCI-other (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). No significant differences between the add-on effect of TMS and the add-on effect of amyloid markers to clinical work-up were observed (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.732), while the diagnostic confidence further increased when both markers were available. The greater the clinical expertise, the greater the flexibility in considering alternative diagnosis, and the greater the ability to modify diagnostic confidence with TMS and amyloid markers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TMS in addition to routine clinical assessment in MCI subjects has a significant effect on diagnostic accuracy and confidence, comparable to well-established biomarkers of amyloidosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-019-0555-3","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:38:21Z","timestamp":1575286701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy"],"prefix":"10.1186","volume":"11","author":[{"given":"Alessandro","family":"Padovani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Benussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Sofia","family":"Cotelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarissa","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Dell\u2019Era","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Turrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Paghera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9814","authenticated-orcid":false,"given":"Barbara","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,1]]},"reference":[{"issue":"3","key":"555_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment. Neurology. 2018;90(3):126\u201335.","journal-title":"Neurology"},{"issue":"7","key":"555_CR2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","volume":"30","author":"JL Price","year":"2009","unstructured":"Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026\u201336.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"555_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837\u201344.","journal-title":"Neurology"},{"issue":"3","key":"555_CR4","first-page":"270","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. JALZ. 2011;7(3):270\u20139.","journal-title":"JALZ"},{"issue":"4","key":"555_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313.","journal-title":"Ann Neurol"},{"issue":"8","key":"555_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669\u201378.","journal-title":"Lancet Neurol"},{"issue":"3","key":"555_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/jnnp.2010.207183","volume":"82","author":"LC de Souza","year":"2011","unstructured":"de Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer\u2019s disease from other cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82(3):240\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"555_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131(6):1630\u201345.","journal-title":"Brain"},{"issue":"12","key":"555_CR9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi M, Altomare D, Ferrari C, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment. JAMA Neurol. 2016;73(12):1417.","journal-title":"JAMA Neurol"},{"issue":"7","key":"555_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer\u2019s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619\u201327.","journal-title":"Lancet Neurol"},{"issue":"7","key":"555_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0000000000004232","volume":"89","author":"A Benussi","year":"2017","unstructured":"Benussi A, Di Lorenzo F, Dell\u2019Era V, et al. Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology. 2017;89(7):665\u201372.","journal-title":"Neurology"},{"issue":"5","key":"555_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from fronto temporal lobar degeneration. Brain. 2018;141(5):1263\u201385.","journal-title":"Brain"},{"issue":"11","key":"555_CR13","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1586\/14737175.7.11.1499","volume":"7","author":"R Tarawneh","year":"2007","unstructured":"Tarawneh R, Galvin JE. Distinguishing Lewy body dementias from Alzheimer\u2019s disease. Expert Rev Neurother. 2007;7(11):1499\u2013516.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"555_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40478-016-0334-3","volume":"4","author":"AA Khundakar","year":"2016","unstructured":"Khundakar AA, Hanson PS, Erskine D, et al. Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathol Commun. 2016;4(1):66.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"555_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.clinph.2015.02.001","volume":"126","author":"PM Rossini","year":"2015","unstructured":"Rossini PM, Burke D, Chen R, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin. Neurophysiol. 2015;126(6):1071\u2013107.","journal-title":"Neurophysiol."},{"issue":"1","key":"555_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JAD-180293","volume":"65","author":"A Padovani","year":"2018","unstructured":"Padovani A, Benussi A, Cantoni V, et al. Diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease with transcranial magnetic stimulation. J Alzheimers Dis. 2018;65(1):221\u201330.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"555_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ana.24731","volume":"80","author":"A Benussi","year":"2016","unstructured":"Benussi A, Cosseddu M, Filareto I, et al. Impaired long-term potentiation-like cortical plasticity in presymptomatic genetic frontotemporal dementia. Ann Neurol. 2016;80(3):472\u20136.","journal-title":"Ann Neurol"},{"issue":"2019","key":"555_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neurobiolaging.2018.12.018","volume":"76","author":"A Benussi","year":"2019","unstructured":"Benussi A, Gazzina S, Premi E, et al. Clinical and biomarker changes in presymptomatic genetic frontotemporal dementia. Neurobiol Aging. 2019;76(2019):133\u201340.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"555_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.brs.2017.11.013","volume":"11","author":"A Benussi","year":"2018","unstructured":"Benussi A, Dell\u2019Era V, Cantoni V, et al. Discrimination of atypical parkinsonisms with transcranial magnetic stimulation. Brain Stimul. 2018;11(2):366\u201373.","journal-title":"Brain Stimul"},{"issue":"1","key":"555_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13195-018-0423-6","volume":"10","author":"A Benussi","year":"2018","unstructured":"Benussi A, Alberici A, Ferrari C, et al. The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease. Alzheimers Res Ther. 2018;10(1):94.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"555_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1468-1331.1996.tb00423.x","volume":"3","author":"E Magni","year":"1996","unstructured":"Magni E, Binetti G, Bianchetti A, et al. Mini-mental state examination: a normative study in Italian elderly population. Eur J Neurol. 1996;3(3):198\u2013202.","journal-title":"Eur J Neurol"},{"issue":"11","key":"555_CR22","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412.","journal-title":"Neurology"},{"issue":"12","key":"555_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185(12):914\u20139.","journal-title":"JAMA"},{"issue":"3","key":"555_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386.","journal-title":"Gerontologist"},{"issue":"12","key":"555_CR25","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308.","journal-title":"Neurology"},{"key":"555_CR26","first-page":"1797536","volume":"2018","author":"G Galeoto","year":"2018","unstructured":"Galeoto G, Sansoni J, Scuccimarri M, et al. A psychometric properties evaluation of the Italian version of the geriatric depression scale. Depress Res Treat. 2018;2018:1797536.","journal-title":"Depress Res Treat"},{"issue":"1\u20132","key":"555_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/21678421.2014.971812","volume":"16","author":"B Borroni","year":"2015","unstructured":"Borroni B, Benussi A, Archetti S, et al. Csf p-tau181\/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Front Degener. 2015;16(1\u20132):86\u201391.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"1","key":"555_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1113\/jphysiol.1993.sp019912","volume":"471","author":"T Kujirai","year":"1993","unstructured":"Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol. 1993;471(1):501\u201319.","journal-title":"J Physiol"},{"issue":"3","key":"555_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1113\/jphysiol.1996.sp021734","volume":"496","author":"U Ziemann","year":"1996","unstructured":"Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol. 1996;496(3):873\u201381.","journal-title":"J Physiol"},{"issue":"Pt 2","key":"555_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1469-7793.2000.t01-1-00503.x","volume":"523","author":"H Tokimura","year":"2000","unstructured":"Tokimura H, Di Lazzaro V, Tokimura Y, et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J. Physiol. 2000;523(Pt 2):503\u201313.","journal-title":"J. Physiol"},{"issue":"4","key":"555_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"555_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376.","journal-title":"Lancet Neurol"},{"issue":"19","key":"555_CR33","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924\u201338.","journal-title":"JAMA"},{"issue":"3","key":"555_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","volume":"14","author":"M Ceccaldi","year":"2018","unstructured":"Ceccaldi M, Jonveaux T, Verger A, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement. 2018;14(3):293\u2013305.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"555_CR35","first-page":"280","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. JALZ. 2011;7(3):280\u201392.","journal-title":"JALZ"},{"key":"555_CR36","first-page":"1","volume":"31","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;31:1\u201311.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"555_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-018-0361-3","volume":"10","author":"RW Paterson","year":"2018","unstructured":"Paterson RW, Slattery CF, Poole T, et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther. 2018;10(1):32.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"555_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer\u2019s Dement. 2011;7(4):386\u201395 e6.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"19","key":"555_CR39","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939\u201349.","journal-title":"JAMA"},{"issue":"10","key":"555_CR40","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.clinph.2014.08.028","volume":"126","author":"U Ziemann","year":"2015","unstructured":"Ziemann U, Reis J, Schwenkreis P, et al. TMS and drugs revisited 2014. Clin Neurophysiol. 2015;126(10):1847\u201368.","journal-title":"Clin Neurophysiol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0555-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:09:27Z","timestamp":1606694967000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0555-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0555-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Full written informed consent was obtained from all participants according to the Declaration of Helsinki. The study protocol was approved by the local ethics committee (#NP1965 approved May 19, 2015).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}